Klotho Neurosciences, Inc. (KLTOW)

Market Cap	64.99M
Revenue (ttm)	n/a
Net Income (ttm)	-7.71M
Shares Out	32.49M
EPS (ttm)	-0.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,136,186
Open	0.3321
Previous Close	0.2445
Day's Range	0.3220 - 0.9500
52-Week Range	0.0100 - 0.9500
Beta	0.02
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 20, 2025

About KLTOW

Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates comprise KLTO-101 for the treatment or prevention of Alzheimer’s disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig’s disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Joseph Sinkule
• Employees: 3
• Stock Exchange: NASDAQ
• Ticker Symbol: KLTOW
• Website: https://klothoneuro.com